Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients

Emmanuelle Comets, Kazumasa Ikeda, Paulo Hoff, Pierre Fumoleau, Jantien Wanders, Yusuke Tanigawara

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. This article presents a population pharmacokinetic analysis of these four compounds in Western cancer patients. The second objective was to compare the pharmacokinetics of S-1 in Western and Japanese patients. Methods: A single dose (25-45 mg/m2) of S-1 was administered to 60 patients. In each patient, 6 concentrations of FT, 5-FU, oteracil and CDHP were measured over 24hr. Using NONMEM, oteracil and CDHP were analyzed separately, and the individual estimates of CDHP parameters were included in the joint analysis of FT and 5-FU. We used validation techniques to assess differences between the two populations, and finally we compared the exposures in Western and Japanese patients using simulations. Results: A compartmental model describing the PK of the 4 compounds was developed. The influence of CDHP on the elimination of 5-FU was well described by an enzymatic inhibition model. The model provided a good fit for all compounds. The pharmacokinetics for 5-FU and oteracil were similar between Western and Japanese patients, but apparent differences in exposure to 5-FU resulted from different total doses due to different body sizes.

Original languageEnglish
Pages (from-to)257-283
Number of pages27
JournalJournal of Pharmacokinetics and Pharmacodynamics
Volume30
Issue number4
DOIs
Publication statusPublished - 2003 Aug

Fingerprint

Pharmacokinetics
Oxonic Acid
Fluorouracil
Antineoplastic Agents
Toxicity
Potassium
Patient Simulation
Tegafur
Prodrugs
Body Size
Population
Half-Life
Neoplasms

Keywords

  • 5-FU
  • Ethnic differences
  • Model validation
  • Oral anticancer drug
  • Population pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Catalysis

Cite this

Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients. / Comets, Emmanuelle; Ikeda, Kazumasa; Hoff, Paulo; Fumoleau, Pierre; Wanders, Jantien; Tanigawara, Yusuke.

In: Journal of Pharmacokinetics and Pharmacodynamics, Vol. 30, No. 4, 08.2003, p. 257-283.

Research output: Contribution to journalArticle

Comets, Emmanuelle ; Ikeda, Kazumasa ; Hoff, Paulo ; Fumoleau, Pierre ; Wanders, Jantien ; Tanigawara, Yusuke. / Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients. In: Journal of Pharmacokinetics and Pharmacodynamics. 2003 ; Vol. 30, No. 4. pp. 257-283.
@article{3a3f0775f03543259251360547ca9920,
title = "Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients",
abstract = "Objective: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. This article presents a population pharmacokinetic analysis of these four compounds in Western cancer patients. The second objective was to compare the pharmacokinetics of S-1 in Western and Japanese patients. Methods: A single dose (25-45 mg/m2) of S-1 was administered to 60 patients. In each patient, 6 concentrations of FT, 5-FU, oteracil and CDHP were measured over 24hr. Using NONMEM, oteracil and CDHP were analyzed separately, and the individual estimates of CDHP parameters were included in the joint analysis of FT and 5-FU. We used validation techniques to assess differences between the two populations, and finally we compared the exposures in Western and Japanese patients using simulations. Results: A compartmental model describing the PK of the 4 compounds was developed. The influence of CDHP on the elimination of 5-FU was well described by an enzymatic inhibition model. The model provided a good fit for all compounds. The pharmacokinetics for 5-FU and oteracil were similar between Western and Japanese patients, but apparent differences in exposure to 5-FU resulted from different total doses due to different body sizes.",
keywords = "5-FU, Ethnic differences, Model validation, Oral anticancer drug, Population pharmacokinetics",
author = "Emmanuelle Comets and Kazumasa Ikeda and Paulo Hoff and Pierre Fumoleau and Jantien Wanders and Yusuke Tanigawara",
year = "2003",
month = "8",
doi = "10.1023/A:1026142601822",
language = "English",
volume = "30",
pages = "257--283",
journal = "Journal of Pharmacokinetics and Pharmacodynamics",
issn = "1567-567X",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients

AU - Comets, Emmanuelle

AU - Ikeda, Kazumasa

AU - Hoff, Paulo

AU - Fumoleau, Pierre

AU - Wanders, Jantien

AU - Tanigawara, Yusuke

PY - 2003/8

Y1 - 2003/8

N2 - Objective: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. This article presents a population pharmacokinetic analysis of these four compounds in Western cancer patients. The second objective was to compare the pharmacokinetics of S-1 in Western and Japanese patients. Methods: A single dose (25-45 mg/m2) of S-1 was administered to 60 patients. In each patient, 6 concentrations of FT, 5-FU, oteracil and CDHP were measured over 24hr. Using NONMEM, oteracil and CDHP were analyzed separately, and the individual estimates of CDHP parameters were included in the joint analysis of FT and 5-FU. We used validation techniques to assess differences between the two populations, and finally we compared the exposures in Western and Japanese patients using simulations. Results: A compartmental model describing the PK of the 4 compounds was developed. The influence of CDHP on the elimination of 5-FU was well described by an enzymatic inhibition model. The model provided a good fit for all compounds. The pharmacokinetics for 5-FU and oteracil were similar between Western and Japanese patients, but apparent differences in exposure to 5-FU resulted from different total doses due to different body sizes.

AB - Objective: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. This article presents a population pharmacokinetic analysis of these four compounds in Western cancer patients. The second objective was to compare the pharmacokinetics of S-1 in Western and Japanese patients. Methods: A single dose (25-45 mg/m2) of S-1 was administered to 60 patients. In each patient, 6 concentrations of FT, 5-FU, oteracil and CDHP were measured over 24hr. Using NONMEM, oteracil and CDHP were analyzed separately, and the individual estimates of CDHP parameters were included in the joint analysis of FT and 5-FU. We used validation techniques to assess differences between the two populations, and finally we compared the exposures in Western and Japanese patients using simulations. Results: A compartmental model describing the PK of the 4 compounds was developed. The influence of CDHP on the elimination of 5-FU was well described by an enzymatic inhibition model. The model provided a good fit for all compounds. The pharmacokinetics for 5-FU and oteracil were similar between Western and Japanese patients, but apparent differences in exposure to 5-FU resulted from different total doses due to different body sizes.

KW - 5-FU

KW - Ethnic differences

KW - Model validation

KW - Oral anticancer drug

KW - Population pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0242330299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242330299&partnerID=8YFLogxK

U2 - 10.1023/A:1026142601822

DO - 10.1023/A:1026142601822

M3 - Article

C2 - 14650374

AN - SCOPUS:0242330299

VL - 30

SP - 257

EP - 283

JO - Journal of Pharmacokinetics and Pharmacodynamics

JF - Journal of Pharmacokinetics and Pharmacodynamics

SN - 1567-567X

IS - 4

ER -